Last reviewed · How we verify
TDI01 suspension
TDI01 suspension is a medication that targets the renin-angiotensin-aldosterone system (RAAS) to treat hypertension.
TDI01 suspension is a medication that targets the renin-angiotensin-aldosterone system (RAAS) to treat hypertension. Used for Hypertension.
At a glance
| Generic name | TDI01 suspension |
|---|---|
| Sponsor | Beijing Tide Pharmaceutical Co., Ltd |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the angiotensin-converting enzyme (ACE), TDI01 suspension reduces the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation and decreased blood pressure. Additionally, the inhibition of ACE also reduces the breakdown of bradykinin, a vasodilatory peptide, further contributing to the antihypertensive effect.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) (PHASE3)
- TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) (PHASE1, PHASE2)
- A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDI01 suspension CI brief — competitive landscape report
- TDI01 suspension updates RSS · CI watch RSS
- Beijing Tide Pharmaceutical Co., Ltd portfolio CI